C4 Therapeutics (CCCC) Capital Expenditures (2019 - 2026)

C4 Therapeutics' Capital Expenditures history runs 8 years deep, the most recent figure standing at $38000.0 for Q1 2026.

• In Q1 2026, Capital Expenditures changed N/A year-over-year to $38000.0; the TTM figure through Mar 2026 stood at $645000.0 (up 258.33% YoY), while the FY2025 annual figure was $607000.0, up 237.22% from the prior year.
• Capital Expenditures was $38000.0 for Q1 2026 at C4 Therapeutics, up from $11000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $3.1 million in Q2 2022 to a low of -$1.8 million in Q3 2022.
• Historically, Capital Expenditures has averaged $87733.3 across 5 years, with a median of $38000.0 in 2026.
• The sharpest annual moves came in 2022 and 2025: Capital Expenditures sank 1000.92% in 2022, then jumped 2161.54% in 2025.
• A 5-year view of Capital Expenditures shows it stood at -$982000.0 in 2022, then tumbled by 56.11% to -$1.5 million in 2023, then soared by 99.74% to -$4000.0 in 2024, then soared by 375.0% to $11000.0 in 2025, then surged by 245.45% to $38000.0 in 2026.
• The last three Capital Expenditures figures came in at $38000.0 (Q1 2026), $11000.0 (Q4 2025), and $302000.0 (Q3 2025), per Business Quant data.